Physician profile
Aimee Cavendish
NPI 1316113160
$5,473.49
in general payments reported to CMS, 2019-2025
43 companies · $835 in 2025
The $835 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,257 · 2020: $467 · 2021: $818 · 2022: $674 · 2023: $797 · 2024: $625 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,257.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,027.22 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Novo Nordisk INC | $624.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $555.58 | 2019-2025 | |
| Glaxosmithkline, LLC. | $380.94 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $354.80 | 2019-2024 | Cyltezo, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $333.48 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $213.11 | 2019-2022 | |
| Lilly USA, LLC | $178.03 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Sanofi-Aventis U.S. LLC | $173.81 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $173.34 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $95.04 | 2023-2024 | Rexulti, Nuedexta |
| Abbott Laboratories | $92.34 | 2021-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Astellas Pharma US INC | $91.56 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $73.63 | 2019-2025 | Austedo Xr |
| Corium, LLC | $73.18 | 2023-2024 | Azstarys |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Cavendish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.